Oncology Institute (NASDAQ:TOI) Director Sells $50,265.41 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively sold 13,333 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $3.77, for a total transaction of $50,265.41. Following the completion of the sale, the director owned 683,721 shares in the company, valued at $2,577,628.17. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Oncology Institute Price Performance

NASDAQ:TOI traded up $0.07 during mid-day trading on Tuesday, hitting $3.84. 1,161,850 shares of the company’s stock traded hands, compared to its average volume of 1,698,535. The company has a debt-to-equity ratio of 14.58, a quick ratio of 1.39 and a current ratio of 1.68. The company has a market cap of $377.78 million, a PE ratio of -6.00 and a beta of 0.17. The firm’s 50 day simple moving average is $3.74 and its 200 day simple moving average is $3.40. The Oncology Institute, Inc. has a 1 year low of $0.17 and a 1 year high of $4.88.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $136.56 million during the quarter, compared to analysts’ expectations of $122.63 million. Oncology Institute had a negative net margin of 13.21% and a negative return on equity of 1,527.21%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new position in shares of Oncology Institute during the 2nd quarter worth $25,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Oncology Institute in the second quarter valued at $32,000. Cetera Investment Advisers increased its stake in Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares during the last quarter. State of Wyoming purchased a new position in Oncology Institute during the second quarter worth about $37,000. Finally, Prelude Capital Management LLC purchased a new position in Oncology Institute during the third quarter worth about $41,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, October 8th. Needham & Company LLC assumed coverage on Oncology Institute in a research report on Tuesday, November 25th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of Oncology Institute in a research note on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Oncology Institute presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.